Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSmall Lymphocytic LymphomaCLL/SLLChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Zulfa Omer
- Target Recruit Count
- 34
- Registration Number
- NCT06978088
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
- Conditions
- Follicular Lymphoma Grade 3A
- Interventions
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 133
- Registration Number
- NCT06961500
- Locations
- 🇨🇳
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Guangzhou, Guangdong, China
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 630
- Registration Number
- NCT06943872
Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
- Conditions
- Granulomatosis With Polyangiitis
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 33
- Registration Number
- NCT06940661
- Locations
- 🇫🇷
Service de Médecine Interne, Centre de reference "Maladies systémiques et autoimmunes rares, en particulier Vascularites nécrosantes et Sclérodermies systémiques", Paris, France
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
- Conditions
- Primary Central Nervous System LymphomaSecondary Central Nervous System Lymphoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT06922604
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Substudy B: CLL Patients
- Conditions
- Relapsed CLLRefractory CLLRefractory Lymphoma
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Paolo Caimi, MD
- Target Recruit Count
- 18
- Registration Number
- NCT06916767
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, Ohio, United States
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients with CLL or SLL
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma (SLL)
- Interventions
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06849713
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 24
- Registration Number
- NCT06824701
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Uta, Salt Lake City, Utah, United States
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT06806033
- Locations
- 🇫🇷
CHU DE RENNES - CHU Pontchaillou, Rennes, France
🇺🇸Alaska Oncology & Hematology, LLC, Anchorage, Alaska, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06656234
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.